Skip to main content

Jeff Lagasse

By Jeff Lagasse | 04:34 pm | April 19, 2021
The J&J scientists said that out of 75,000 participants in a clinical trial, there was just one case of cerebral venous sinus thrombosis.
By Jeff Lagasse | 01:50 pm | April 19, 2021
While none are officially FDA approved, the agency has cleared them under emergency use authorization.
By Jeff Lagasse | 04:29 pm | April 16, 2021
Round 2 is a $249.95 million federal initiative that builds on the $200 million program established as part of the CARES Act.
By Jeff Lagasse | 11:19 am | April 16, 2021
The signees view the lack of a second application period as a hindrance to the move toward value-based care.
By Jeff Lagasse | 04:33 pm | April 15, 2021
Revenues, profit and earnings per share all saw increases both month-over-month and year-over-year.
By Jeff Lagasse | 01:25 pm | April 15, 2021
Average seller size by revenue was $676 million, well above historical averages for the first quarter and for recent year-end averages.
By Jeff Lagasse | 04:01 pm | April 14, 2021
Vaccine opposition at a social media event inspired the creation of new guidelines to combat misinformation.
By Jeff Lagasse | 02:04 pm | April 14, 2021
The pandemic has acted as an accelerant for the development and evolution of these technologies.
By Jeff Lagasse | 03:43 pm | April 13, 2021
The goal of the partnership is to enhance care by enabling members to receive certain healthcare services in their homes.
By Jeff Lagasse | 12:06 pm | April 13, 2021
Many beneficiaries with end-stage kidney disease suffer from poor health outcomes and face increased risk of complications.